IgG Propels Atherosclerosis by Noncanonically Activating Macrophages

This study reveals that IgG drives atherosclerosis by noncanonically activating macrophages as an endogenous TLR4 ligand, independent of antigen binding, which triggers inflammatory signaling and foam cell formation via the FcRn receptor.

The Gist

The Big Picture: A Case of Mistaken Identity

Imagine your arteries are like the highways of your body, and your immune system is the police force designed to keep them safe.

For a long time, scientists thought the main troublemakers on these highways were "bad cholesterol" (LDL) clogging the roads. They also knew that the police (immune cells) sometimes got confused and started fighting the road itself, causing traffic jams called plaque.

This paper discovers a new, surprising culprit: IgG.

IgG is a type of antibody. Think of IgG as a highly abundant, well-meaning security guard in your blood. Usually, this guard's job is to spot specific bad guys (like viruses) and neutralize them. But this study found that in people with heart disease, these security guards are getting stuck in the arterial "highways," causing chaos even when there are no specific bad guys to fight.

The Story in Three Acts

Act 1: The Security Guard Gets Stuck (Accumulation)

In a healthy body, security guards (IgG) patrol the blood and then leave. But in clogged arteries, something goes wrong.

• The Trap: There is a special recycling machine in the artery walls called FcRn. Think of FcRn as a VIP lounge that usually helps security guards get recycled and stay in circulation.
• The Glitch: In diseased arteries, this VIP lounge goes into overdrive. It grabs the security guards (IgG) and keeps them trapped inside the arterial wall.
• The Result: The more severe the heart disease, the more security guards are trapped inside the plaque. The study found that patients with high levels of trapped IgG had worse heart outcomes.

Act 2: The Guard Goes Rogue (Inflammation)

Once these security guards are trapped in the arterial wall, they don't just sit there. They start acting like a rogue mob.

• The Trigger: Usually, a security guard only attacks if it sees a specific criminal (an antigen). But this study found that IgG doesn't need a criminal to start a fight.
• The Alarm Bell: The trapped IgG hits a giant red alarm button on the macrophages (the "trash collectors" of the artery) called TLR4.
• The Explosion: Hitting this button sets off a chain reaction (NF-κB and NLRP3). It's like the trash collectors suddenly thinking the whole city is on fire. They start screaming inflammatory signals (like IL-1β), making the plaque angry, swollen, and unstable. This makes the plaque more likely to rupture, causing a heart attack.

Crucial Discovery: The study proved that the security guard doesn't need its "eyes" (the part that recognizes specific criminals) to hit the alarm button. Just the body of the guard (the Fc part) is enough to cause the explosion. This means any IgG, even from healthy people, can cause this damage if it gets trapped.

Act 3: The Trash Collectors Get Fat (Foam Cells)

The angry trash collectors (macrophages) do two bad things:

1. They eat up more bad cholesterol.
2. They turn into foam cells (fat-laden cells that look like bubbles).

The study found that the trapped IgG tells the trash collectors to produce a protein called LCN2. Think of LCN2 as a magnet that pulls more bad cholesterol into the cells. The more IgG trapped, the more LCN2 is made, and the fatter the cells get. These fat-filled cells are the main building blocks of the dangerous plaque that clogs your arteries.

The Solution: A New Way to Fix the Highway

The researchers tested a new idea: What if we stop the security guards from getting trapped?

They used mice with heart disease and genetically removed the "VIP lounge" (FcRn) specifically in the trash collectors.

• The Result: Without the VIP lounge, the security guards couldn't get stuck in the arterial wall.
• The Outcome: The inflammation stopped, the trash collectors stayed lean, and the plaque shrank significantly.
• The Bonus: This happened without changing the mice's cholesterol levels or weight. It proves that the problem wasn't just the cholesterol; it was the trapped security guards.

Why This Matters for You

1. It's Not Just About Cholesterol: Even if you lower your cholesterol with drugs, you might still have heart risk if this "trapped guard" mechanism is active.
2. A New Target: There are already drugs (like Nipocalimab) that block this VIP lounge (FcRn). This paper suggests these drugs could be repurposed to treat heart disease by clearing out the trapped IgG.
3. The Bridge Between Systems: This study shows how the "Adaptive" immune system (the specific police) accidentally hijacks the "Innate" immune system (the general defense), causing chronic inflammation.

The Takeaway Metaphor

Imagine your artery is a highway.

• Cholesterol is the trash piling up on the side.
• IgG is the police force.
• FcRn is a broken traffic light that keeps the police cars stuck in a gridlock on the road.
• Because they are stuck, the police cars start honking their horns (inflammation) and blocking the lanes (foam cells), causing a massive pile-up (heart attack).

This paper says: "Don't just clear the trash; fix the traffic light so the police cars can move on, and the gridlock will clear up."

Technical Summary

1. Problem Statement

Cardiovascular disease (CVD), driven primarily by atherosclerosis, remains a leading cause of global mortality. Despite effective lipid-lowering therapies (e.g., statins), a significant "residual risk" persists. While the role of innate immunity and oxidized LDL (oxLDL) in atherogenesis is well-established, the contribution of the adaptive immune system, specifically Immunoglobulin G (IgG), has been largely overlooked or attributed solely to antigen-specific immune complex formation. The authors hypothesize that IgG may drive atherosclerosis through a noncanonical mechanism, independent of its classical antigen-binding function, potentially bridging adaptive and innate immunity to exacerbate plaque inflammation and instability.

2. Methodology

The study employed a multi-disciplinary approach integrating human clinical data, genetic mouse models, and molecular biology techniques:

• Human Clinical Cohorts:
  • Proteomics: Data-independent acquisition (DIA) proteomic profiling of 233 coronary artery segments (98 CAD patients vs. 14 healthy donors) to quantify IgG isoforms and FcRn (Fc neonatal receptor).
  • Single-Cell Analysis: Integration of CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) and scRNA-seq data from human carotid plaques to map IgG and FcRn expression at single-cell resolution.
  • Clinical Correlation: Kaplan-Meier survival analysis linking tissue IgG/FcRn/LCN2 levels to Major Adverse Cardiac and Cerebrovascular Events (MACCE) in the Fuwai and BiKE cohorts.
• Mouse Models:
  • Genetic Ablation: Myeloid-specific FcRn knockout (mKO) mice ($LysM-Cre \times FcRn^{fl/fl}$) transplanted into $Ldlr^{-/-}$ recipients (Bone Marrow Transplantation model) and AAV-PCSK9 hypercholesterolemia models.
  • Intervention: Treatment with FcRn inhibitors (Nipocalimab) and pharmacological inhibitors of TLR4, NF-κB, NLRP3, and LCN2.
• In Vitro Mechanistic Studies:
  • Cell Lines: Bone marrow-derived macrophages (BMDMs), RAW264.7, and THP-1 human macrophages.
  • Stimuli: Native IgG, boiled/denatured IgG, Fab fragments, Fc fragments, and specific antibodies (anti-PD1).
  • Techniques: Western blotting, qPCR, immunofluorescence (IF), Surface Plasmon Resonance (SPR), and TurboID proximity labeling to identify direct protein interactions.

3. Key Contributions

• Discovery of a Noncanonical Pathway: The study identifies IgG as a direct endogenous ligand for Toll-like Receptor 4 (TLR4), activating innate immune signaling (NF-κB/NLRP3) without requiring antigen recognition or Fcγ receptor (FcγR) engagement.
• Role of FcRn in Plaque Accumulation: It establishes that the recycling receptor FcRn is the primary driver of IgG accumulation within atherosclerotic plaques, specifically in pro-inflammatory and foamy macrophages, rather than local B-cell production.
• Downstream Effector Identification: The study identifies Lipocalin-2 (LCN2) as the critical downstream effector linking IgG-induced TLR4/NF-κB signaling to macrophage foam cell formation.
• Therapeutic Implication: It suggests that targeting the FcRn-IgG axis (e.g., with Nipocalimab) could reduce atherosclerosis without compromising the broader adaptive immune system, unlike B-cell depletion strategies.

4. Key Results

A. Clinical and Proteomic Evidence

• IgG and FcRn Correlation: Proteomic analysis of human coronary plaques revealed significantly elevated levels of all four IgG heavy-chain isoforms (IGHG1–4) and FcRn in severe (core) plaques compared to mild plaques and healthy controls.
• Clinical Outcomes: High plaque levels of IGHG1, IGHG2, and IGHG4 correlated with a trend toward shorter event-free survival. Conversely, higher IGHG3 was associated with better outcomes (potentially due to its weak FcRn binding and short half-life).
• Cellular Localization: Single-cell analysis localized FcRn and surface IgG Fc predominantly to pro-inflammatory (IL1Bhi, C1Qhi) and foamy macrophages in symptomatic plaques.

B. In Vivo Mechanism: FcRn Drives Accumulation and Disease

• Macrophage Dependency: In myeloid-specific FcRn knockout (mKO) mice transplanted into $Ldlr^{-/-}$ recipients, plaque IgG accumulation was nearly abolished.
• Atherosclerosis Attenuation: mKO mice exhibited a >30% reduction in aortic root lesion area, reduced necrotic core size, and decreased acellular areas compared to controls.
• Metabolic Independence: These protective effects occurred without changes in body weight, glucose tolerance, or total cholesterol, confirming a direct pro-atherogenic role for plaque IgG independent of systemic lipid metabolism.
• Inflammation: Plaque macrophage burden (CD68+) and proliferation (Ki67+) were reduced, along with decreased IL-1β levels.

C. Molecular Mechanism: IgG as a TLR4 Ligand

• Innate Activation: Treatment of macrophages with native IgG (but not boiled/denatured IgG) induced robust NF-κB phosphorylation, nuclear translocation, and NLRP3 inflammasome activation (ASC speck formation).
• TLR4 Dependence: The inflammatory response was completely blocked by the TLR4 inhibitor TAK242 and absent in TLR4-deficient ($TLR4^{lps-del}$) macrophages.
• Non-Canonical Activation:
  • Fab vs. Fc: The Fc fragment alone was sufficient to activate NF-κB, while the Fab fragment was not.
  • Antigen Independence: A monoclonal anti-PD1 antibody (hPD1 mAb) also triggered inflammation, and this was blocked by TAK242, proving antigen specificity is not required.
  • Direct Binding: Surface Plasmon Resonance (SPR) and TurboID proximity labeling confirmed that IgG binds directly to the TLR4/MD2 complex.

D. Foam Cell Formation via LCN2

• LCN2 Upregulation: IgG treatment upregulated Lcn2 expression in a TLR4/NF-κB-dependent manner.
• Foam Cell Phenotype: IgG enhanced oxLDL uptake in macrophages. This effect was blocked by TLR4 inhibition and LCN2 inhibition (ZINC00640089), but not by NLRP3 inhibition, indicating the foam cell mechanism is distinct from inflammasome activation.
• Clinical Validation: High plaque LCN2 levels correlated with adverse clinical events in human cohorts.
• Therapeutic Proof: The clinically approved FcRn antibody Nipocalimab successfully blocked IgG-induced foam cell formation in human THP-1 macrophages.

5. Significance

This paper fundamentally redefines the role of IgG in atherosclerosis, shifting the paradigm from a passive marker or antigen-specific immune complex driver to an active, noncanonical pro-atherogenic mediator.

• Mechanistic Insight: It reveals a direct molecular bridge where an adaptive immune molecule (IgG) activates innate immunity (TLR4) to drive chronic inflammation and lipid accumulation.
• Therapeutic Potential: The findings suggest that FcRn inhibition (e.g., Nipocalimab) offers a novel therapeutic strategy to reduce cardiovascular risk by clearing pathogenic IgG from plaques and dampening macrophage activation, potentially benefiting high-risk populations (e.g., aging, obese) without the immunosuppressive risks of B-cell depletion.
• Biomarker Value: Plaque levels of IgG, FcRn, and LCN2 serve as potential biomarkers for disease severity and adverse outcomes.